A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors

Protocol: 
AAAQ9545
Phase: 
I

A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors

The purpose of this study is to test the safety of the combination of the study drugs MM-398 and ABT-888 (veliparib). MM-398 has been approved by the FDA for advanced pancreatic cancer. ABT-888 (veliparib) has been tested in participants with various tumor types. This study tests different doses of the combination of these drugs to see which combination of doses is safer in people. There will be about 48 people taking part in this study.

Are you Eligible? (Inclusion Criteria)

-Patients must have pathologically confirmed diagnosis of a solid tumor
cancer for which there is no known standard therapy capable of extending
life expectancy..
-Prior PARP inhibitor therapy is allowed. Patients with ovarian cancer and a
BRCA mutation should have had prior treatment with olaparib per guidelines
for standard of care treatment.
-Age ≥18 years.
-ECOG performance status ≤2